Our data suggest that the combinational effects of BRCA1/BRCA2 germline mutations, along with the high frequency of LOH events and somatic TP53 mutations result in aggressive basal subtype breast cancer and ovarian cancer. The gene discussed is BRCA1; the disease is breast carcinoma.